In Part II of our discussion with DARA Biosciences (NASDAQ: DARA) CEO and Chief Medical Officer Dr. David Drutz, we look into key catalysts for the specialty pharmaceutical company. Dr. Drutz discusses the medical need for the oral-liquid tamoxifen, Soltamox, licensed to DARA by UK-based Rosemont Pharmaceuticals — as well as the market opportunity in developing oncology services.
Browsing: NEWS
1) Findings: Insights and developments globally on the subject.
2) Companies: Updates and progress reports on member companies.
3) Industry: Important developments from throughout the field.
DARA Biosciences has created some buzz as of late, landing on several ‘watch lists’ after the company’s exclusive licensing of three market-ready products for distribution in the United States. CEO/Chief Medical Officer Dr. David Drutz and COO Chris Clement conducted a two-part interview with OneMedRadio discussing developmental milestones and key catalysts for Q4-2012 and 2013.
This is Part I of our special report on the state of immunotherapy in the public markets. This report looks at promising anticancer immunotherapy technologies, and the major issues in bringing these technologies to the general public.
Colby Pharmaceutical Company (Colby), a privately held San Jose, CA based biopharmaceutical company, announced that it has acquired Othera Pharmaceuticals Inc. (Othera) of Conshohocken, PA.
Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a clinical-stage biopharmaceutical company developing drugs for sexual dysfunction, inflammatory diseases and ophthalmological conditions has announced a manufacturing agreement with drug delivery maker Enthypharm Ltd for Zertane, Ampio’s drug for the treatment of premature ejaculation (PE).
The San Diego-based pharmaceutical company has five approved products internationally, covering erectile dysfunction (Vitaros), side effects of cancer therapy (Totect and Granisol), coronary artery disease (Nitromist) and dry mouth (Aquoral). After a series of successes in strategic partnerships, acquisitions, peer review and clinical data in Q3, the company is garnering some serious attention.
September is Sickle Cell Awareness Month, a time when the medical community will gather with the patient population in the hopes of advancing research in this significant unmet medical need. One company, ADVENTRX Pharmaceuticals [NYSE: ANX], is attempting to engage the investor community and the sector’s most promising drug developers through the First Annual Sickle Cell Disease Therapeutics Conference, taking place September 19th, 2012 in New York City.
In this special series, we explore the state of select public companies operating in a particularly intriguing area of life sciences. This week, we look at metastatic cancer, an area of significant unmet need. These companies, including OncoSec Medical, are having success with their innovative approaches to treating metastatic cancer, and are seeing results in their performance int he public markets.